ImageneBio vs ProKidney
IMA and PROK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMA and PROK compare
ProKidney is the larger company, worth 8.1 times as much as ImageneBio ($342M against $42.2M).
ImageneBio scores higher on the StockData Score (7 against 5 for ProKidney), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMA | PROK |
|---|---|---|
| Size and price | ||
| Market cap | $42.2M | $342M |
| Share price | $3.72 | $1.13 |
| Change, 1 year | −54.6% | −58.1% |
| Change, 5 years | −98.0% | −88.6% |
| Beta (5Y) | 1.18 | 1.32 |
| Employees | 15 | 231 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 418× |
| P/B | 0.3× | – |
| FCF yield | – | −46.8% |
| Growth | ||
| Revenue growth (TTM) | – | 55.2% |
| Revenue growth, 5Y average | −38.6% | – |
| Profitability | ||
| Operating margin | – | −21665% |
| Net margin | – | −10288% |
| FCF margin | – | −19527% |
| Return on equity | −32.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −9327.2× |
| Current ratio | 16.17 (better) | 8.36 |
| Altman Z-score | −0.99 (better) | −1.12 |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −7.1% |
| Shareholder yield | 0.00% (better) | −7.1% |
| Ownership | ||
| Held by institutions | 54.9% | 16.1% |
| Held by insiders | 52.9% | 62.9% |
| Insider net buying, 12 months | $78.5K (better) | −$1.1M |
| Short interest, % of float | 0.86% | 21.7% |
Go deeper
- IMA stock overview
- IMA income statement
- IMA valuation and score
- PROK stock overview
- PROK income statement
- PROK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.